B. Braun Receives FDA Approval of Daytona Beach Pharmaceutical Manufacturing Site
- B.Braun Medical, Inc.
BETHLEHEM, Pa., Jan. 28, 2022 /PRNewswire/ — B. Braun Medical Inc. (B. Braun), a leader in infusion therapy and pain management, today announced that the company has received final approval by the U.S. Food & Drug Administration (FDA) for its new pharmaceutical manufacturing plant in Daytona Beach, FL. The site will produce 0.9% Sodium Chloride for Injection available in B. Braun’s Excel® Plus IV Bags in 1,000 mL and 500 mL sizes. Consistent with B. Braun’s decades-long commitment to protect patients from exposure to harmful chemicals, the Excel Plus IV bags are not made with PVC, DEHP or natural rubber latex. Read more…
Related Reading
Event / Emerging Policy Response Resources / Global & Trade / Government & Legislative Affairs / Supply Chain / Tariffs
The Kennedy v Braidwood Ruling: What’s Next for MedTech
July 17, 2025
2:00 PM – 3:30 PM
Join AdvaMed and Reed Smith experts to explore how the Supreme Court’s ACA ruling in Braidwood could shape preventive care and MedTech policy.
Resource / Coverage & Payment / Emerging Policy Response Resources / Global & Trade / Supply Chain / Tariffs
Supreme Court’s Decision in Kennedy v. Braidwood Management, Inc.
July 2, 2025
Explore the impact of the Supreme Court’s decision in Kennedy v. Braidwood on the ACA preventive services mandate and its implications for MedTech policy.
Resource / Emerging Policy Response Resources / Tariffs
Tariff-related Litigation Update – 6/27
June 30, 2025
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through June 17, 2025.
Resource / Emerging Policy Response Resources / Tariffs
Tariff-related Litigation Update – 6/20
June 20, 2025
Member-only summary of IEEPA “fentanyl” and reciprocal tariffs under EO 14257, plus status of related legal challenges across federal courts through June 17, 2025.
Resource / Emerging Policy Response Resources / Tariffs
Tariff-related Litigation Update
June 16, 2025
Explore the latest IEEPA tariff developments and legal challenges, including executive orders on fentanyl tariffs and reciprocal duties affecting global MedTech trade.
Blog / Global & Trade / Government & Legislative Affairs / Regulatory Affairs / Tariffs
Medtech is Essential: Industry Supports Call for Tariff Flexibility
May 29, 2025
AdvaMed President and CEO Scott Whitaker testified before the U.S. Senate Finance Committee, bringing attention to the pressing issue of how tariffs could impact the medtech industry and, most importantly, the patients who depend on it.
Event / Emerging Policy Response Resources / Global & Trade / Government & Legislative Affairs / Supply Chain / Tariffs
URGENT: Court Ruling on Tariffs — Implications for Medtech
Now On Demand!
Emergency Briefing on Court Ruling on Tariffs and Its Impact on Medtech. Now On Demand!
Blog / Government & Legislative Affairs / Regulatory Affairs
Orthogonal, Kwame Ulmer on the Value of AdvaMed Membership
May 20, 2025
At AdvaMed, we’re proud to be recognized for our work on behalf of the medtech community – and we’re especially grateful when that recognition comes from respected voices like Kwame Ulmer of MedTech Impact Partners and our colleagues at Orthogonal.